References
- Kudo-Saito C, Schlom J, Hodge RV. Intratumoral vaccination and diversified subcutaneousiintratumoral vaccination with recombinant poxviruses encoding a tumor antigen and multiple costimulatory molecules. Clin. Cancer Res. 10(3), 1090–1099 (2004).
- Hodge JW, Poole DJ, Aarts WM et al. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses. Cancer Res. 63(22), 7942–7949 (2003).
- Marshall J. Carcinoembryonic antigen- based vaccines. Semin. OncoL 30 (Suppl. 8), 30–36 (2003).
- •Overview of the clinical experience pre-TRICOM.
- Kaufman HL, Cheung K, Haskell Z et al. Clinical protocol. Intra-lesional rF-B7.1 versus rF-TRICOM vaccine in the treatment of metastatic cancer. Hum. Gene Ther. 14(8), 803–827 (2003).
- Scholm J, Sabzevari H, Grosenbach DW, Hodge JW. A triad of costimulatory molecules synergize to amplify T-cell activation in both vector-based and vector-infected dendritic cell vaccines. Art]! Cells Blood Substit. ImmobiL BiotechnoL 31(2), 193–228 (2003).
- Hodge JW, Grosenbach DW, Aarts WM, Poole DJ, Schlom J. Vaccine therapy of established tumors in the absence of autoimmunity. Clin. Cancer Res. 9(5), 1837–1849 (2003).
- Briones J, Timmerman JM, Panicalli DL, Levy R. Antitumor immunity after vaccination with B lymphoma cells overexpressing a triad of costimulatory molecules. J Natl Cancer Inst. 95 (7), 548–555 (2003).
- Oh S, Hodge JW, Ahlers JD etal. Selective induction of high avidity CTL by altering the balance of signals from APC. ImmunoL 170(5), 2523–2530 (2003).
- Greiner JW, Zeytin H, Anver M, Scholm J. Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res. 62 (23), 6944–6951 (2002).
- Aarts WM, Schlom J, Hodge RV. Vector- based vaccinacytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res. 62 (20), 5770–5777 (2002).
- Shankar P, Schlom J, Hodge RV. Enhanced activation of rhesus T-cells by vectors encoding a triad of costimulatory molecules (B7-1, ICAM-1, LFA-3). Vaccine 20 (5–6), 744–755 (2001).
- Morse MA. Technology evaluation: CEA-TRICOM, Therion Biologics Corp. CUIT: Opin. MoL Ther. 3(4), 407–412 (2001).
- Kaufman HL, DeRaffele G, Divito J et al A Phase I trial of intralesional rV-Tricom vaccine in the treatment of malignant melanoma. Hum. Gene Ther. 12(11) 1459–1480 (2001).
- Rad AN, Schlom J, Hodge JW. Vector- driven hyperexpression of a triad of costimulatory molecules confers enhanced T-cell stimulatory capacity to DC precursors. Crit. Rev OncoL HematoL 39(1–2), 43–57 (2001).
- Grosenbach DW, Barrientos JC, Scholm J, Hodge RV. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res. 61 (11), 4497–4505 (2001).
- Hodge JW, Grosenbach DW, Rad AN et al. Enhancing the potency of peptide-pulsed antigen-presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules. Vaccine 19(25-26), 3552–3567 (2001).
- Zhu M, Terasawa H, Gulley J et al Enhanced activation of human T-cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells. Cancer Res. 61(9), 3725–3734 (2001).
- Gray K. Heads up on osteoporosis. JSC Med. Assoc. 97(2), 53–56 (2001).
- Hodge JW, Rad AN, Grosenbach DW et al. Enhanced activation of T-cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules. J Natl Cancer Inst. 92(15), 1228–1239 (2000).
- Hodge JW, Sabrezevari H, Yafal AG et al A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res. 59(22), 5800–5807 (1999).
- •Prechnical data supports the use of TRICOM.
- Bernstein N. Overview of therapeutic vaccination approaches for cancer. Semin. One& 30(3 Suppl. 8), 1–8 (2003).